Pertuzumab and trastuzumab are monoclonal antibodies that bind to different sites of the human epidermal growth factor receptor 2 (HER2), but together have a synergistic cytotoxic effect on HER2 over-expressed cancer cells [6]. The gene discussed is ERBB2; the disease is cancer.